Search clinical trials for: OMS302 Solution

Total 19171 results

Omeros Corporation

Completed

Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.

Cataract Extraction

United States
Omeros Corporation

Completed

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

Cataract

United States
Omeros Corporation

Terminated

Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery

Intraocular Lens Replacement | Intraoperative Floppy Iris Syndrome

Austria, Germany
IntraPace, Inc

Completed

Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102

Obesity | Morbid Obesity

Germany
Omeros Corporation

Completed

Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones

Urinary Calculi | Renal Calculi | Kidney Stones | Urinary Stones | Urinary Tract Stones

United States
Omeros Corporation

Completed

Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones

Urinary Calculi | Urinary Stones | Urinary Tract Stones

United States
Omeros Corporation

Completed

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification (OMS302-ILR-004)

Intraocular Lens Replacement

United States, Netherlands
Omeros Corporation

Completed

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification (OMS302-ILR-003)

Intraocular Lens Replacement

United States
Omeros Corporation

Recruiting

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 Glomerulopathy | Idiopathic Immune Complex-Mediated Glomerulonephritis

Lithuania, New Zealand, Poland, Tunisia, Turkey, United Kingdom
EMS

Not yet recruiting

Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss (GENERA)

Female Pattern Baldness

Brazil
Omeros Corporation

Recruiting

Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Ukraine
LaNova Medicines Zhejiang Co., Ltd.

Recruiting

A LM-302 Combined With Toripalimab Phase II Study

Gastric Cancer | Pancreatic Cancer

China
Omeros Corporation

Recruiting

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Switzerland, Germany, Ukraine, United Kingdom
Ipsen

Terminated

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

Breast Cancer

Austria
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Fecal Microbiota Transfer to Improve Diabetes Control Post-bariatric Surgery (DRIFTER)

Type 2 Diabetes | Bariatric Surgery

France
Ipsen

Completed

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Gastroenteropancreatic Neuroendocrine Tumors

Switzerland
Ipsen

Completed

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Gastro-Enteropancreatic Neuroendocrine Tumor

United States, Austria, Denmark
Imperial College London
European Commission

Withdrawn

Modelling the Interaction Between Synthetic Model Immunogens and the Induced B and T Cell Repertoires. (MOSAIC)

Virus Diseases

United Kingdom
Aldeyra Therapeutics, Inc.

Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye Syndromes

United States
Baskent University

Unknown

Comparison of the Effects of Crystalloid Cardioplegia and HTK Solution for Postoperative Troponin-I and CK-MB Levels After Pediatric Cardiac Surgery

Myocardial Injury

Turkey
Sylentis, S.A.

Completed

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

Dry Eye Disease

Spain, Portugal, Italy, Estonia, Germany, Slovakia
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
ORA, Inc.
Palatin Technologies, Inc

Completed

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

Dry Eye Disease

United States
Mimetogen Pharmaceuticals USA, Inc.

Active, not recruiting

Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye Syndromes | Dry Eye Disease | Kerato Conjunctivitis Sicca

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Dry Eye

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

Keratoconjunctivitis Sicca

United States
Washington University School of Medicine
Quest Medical, Inc

Recruiting

Effects of Microplegia on Transfusion Rates After Cardiac Surgery

Aortic Valve Disease | Mitral Valve Disease

United States
HanAll BioPharma Co., Ltd.

Completed

A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes (VELOS-1)

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Dry Eye Syndromes

Canada
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (DROPS-2)

Chronic Graft-versus-host Disease

United States
OcuTerra Therapeutics, Inc.

Completed

Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)

Diabetic Macular Edema

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Allergic Conjunctivitis

Canada
Aerpio Therapeutics

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Santen Pharmaceutical Co., Ltd.

Completed

Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Persistent Corneal Epithelial Defect

Japan
VivaVision Biotech, Inc

Not yet recruiting

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease

Dry Eye

China
Sylentis, S.A.

Completed

Safety Study of Tivanisiran to Treat Dry Eye (FYDES)

Dry Eye Disease

United States
The Hospital for Sick Children

Completed

Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal

Chronic Dialysis Patients

Canada
Aerie Pharmaceuticals

Completed

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Santen Pharmaceutical Asia Pte. Ltd.

Recruiting

Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl (NOPAPS)

Ocular Hypertension | Primary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma, Suspect

Korea, Republic of
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

Canada
Sylentis, S.A.

Completed

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

Dry Eye Disease | Sjögren Syndrome

United States, Spain
ORA, Inc.
Topivert Pharma Ltd

Completed

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

Dry Eye Syndrome

United States

3

Subscribe